Tag: licenses

ROAD TOWN, British Virgin Islands, Aug. 02, 2025 (GLOBE NEWSWIRE) -- The recent Ethereum bull run has renewed momentum across the blockchain space, drawing increased attention to emerging platforms that combine utility with innovation. Among them, Ozak AI is gaining investor interest as it announces the launch of Stage 4 of its $OZ token presale, now priced at $0.005.

LUXEMBOURG , Aug. 02, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift, a blockchain protocol combining Proof-of-Work (PoW), Proof-of-Stake (PoS), and an AI-powered Proof-of-Yield (PoY) mechanism, has officially entered Stage 3 of its presale. The platform is offering tokens at $3 during this limited 64-day window, with a scheduled increase to $4 in the next stage and a confirmed launch price of $15.

SINGAPORE, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ostium, a decentralized trading platform, has announced the launch of a new leveraged trading instrument: 0DTE perpetuals for equities. The instrument combines intraday expiry with perpetual structure, offering day traders up to 100x leverage on individual stocks during market hours — a structural innovation aimed at addressing the limitations of traditional options and CFDs.

ROAD TOWN, British Virgin Islands, Aug. 01, 2025 (GLOBE NEWSWIRE) -- OZAK AI has made a significant impact in the crypto and AI investment sector. It is capturing serious attention after completing its Certik audit (considered to be the best benchmark of security in blockchain projects worldwide) and raising over $1.5 million, with its presale ongoing, at just $0.005 per token.

PANAMA CITY, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Gate US, the localized platform powered by global crypto leader Gate Group, has officially launched in the United States, now offering spot trading services tailored for U.S. customers. With a focus on security, simplicity, and regulatory compliance, Gate US aims to provide a seamless crypto trading experience supported by world-class infrastructure and trusted industry expertise.

HTX Hot Listings Weekly Recap

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

Samsung arbitration decision and new HP license agreement drive Q2 results, exceeding outlook
Annualized recurring revenue¹, at all-time high of $553 million, up 44% YoY
Company raises full year 2025 revenue guidance by $110 million